These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 7721254

  • 1. Estrogens and progestins in postmenopausal women: influence on lipid parameters and cardiovascular risk.
    Bruckert E, Turpin G.
    Horm Res; 1995; 43(1-3):100-3. PubMed ID: 7721254
    [Abstract] [Full Text] [Related]

  • 2. Three-year study of estrogen alone versus combined with progestin in postmenopausal women with or without hypercholesterolemia.
    Sanada M, Nakagawa H, Kodama I, Sakasita T, Ohama K.
    Metabolism; 2000 Jun; 49(6):784-9. PubMed ID: 10877207
    [Abstract] [Full Text] [Related]

  • 3. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease.
    Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH.
    N Engl J Med; 1996 Aug 15; 335(7):453-61. PubMed ID: 8672166
    [Abstract] [Full Text] [Related]

  • 4. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM, Fini M.
    Int J Fertil Womens Med; 2001 Aug 15; 46(5):248-56. PubMed ID: 11720197
    [Abstract] [Full Text] [Related]

  • 5. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P, Walden C, Knopp R, Hoover J, Wallace R, Heiss G, Rifkind B.
    N Engl J Med; 1983 Apr 14; 308(15):862-7. PubMed ID: 6572785
    [Abstract] [Full Text] [Related]

  • 6. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH, Walden CE, Wahl PW, Hoover JJ, Warnick GR, Albers JJ, Ogilvie JT, Hazzard WR.
    J Clin Endocrinol Metab; 1981 Dec 14; 53(6):1123-32. PubMed ID: 7298796
    [Abstract] [Full Text] [Related]

  • 7. Lipid and lipoprotein changes in relation to oral contraception and hormonal replacement therapy.
    Burkman RT.
    Fertil Steril; 1988 May 14; 49(5 Suppl 2):39S-50S. PubMed ID: 3282934
    [Abstract] [Full Text] [Related]

  • 8. Postmenopausal women and cardiovascular risk: impact of hormone replacement therapy.
    Rosano GM, Fini M.
    Cardiol Rev; 2002 May 14; 10(1):51-60. PubMed ID: 11790270
    [Abstract] [Full Text] [Related]

  • 9. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women.
    Psaty BM, Heckbert SR, Atkins D, Siscovick DS, Koepsell TD, Wahl PW, Longstreth WT, Weiss NS, Wagner EH, Prentice R.
    Arch Intern Med; 1993 Jun 28; 153(12):1421-7. PubMed ID: 8512434
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III).
    Herrington DM, Fong J, Sempos CT, Black DM, Schrott HG, Rautaharju P, Bachorik PS, Blumenthal R, Khan S, Wenger NK.
    Am Heart J; 1998 Jul 28; 136(1):115-24. PubMed ID: 9665228
    [Abstract] [Full Text] [Related]

  • 11. Effects of high-intensity training on cardiovascular risk factors in premenopausal and postmenopausal women.
    Mandrup CM, Egelund J, Nyberg M, Lundberg Slingsby MH, Andersen CB, Løgstrup S, Bangsbo J, Suetta C, Stallknecht B, Hellsten Y.
    Am J Obstet Gynecol; 2017 Apr 28; 216(4):384.e1-384.e11. PubMed ID: 28024987
    [Abstract] [Full Text] [Related]

  • 12. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women.
    Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, Siscovick DS, Wagner EH.
    Arch Intern Med; 1994 Jun 27; 154(12):1333-9. PubMed ID: 8002685
    [Abstract] [Full Text] [Related]

  • 13. Noncontraceptive estrogen use and cardiovascular disease.
    Bush TL, Barrett-Connor E.
    Epidemiol Rev; 1985 Jun 27; 7():89-104. PubMed ID: 2996919
    [Abstract] [Full Text] [Related]

  • 14. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS).
    Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, Barrett-Connor E, Hulley SB.
    Circulation; 2001 Feb 06; 103(5):638-42. PubMed ID: 11156873
    [Abstract] [Full Text] [Related]

  • 15. Low-dose oral contraceptives: progestin potency, androgenicity, and atherogenic potential.
    Ellis J.
    Clin Ther; 1986 Feb 06; 8(6):607-18. PubMed ID: 3539347
    [Abstract] [Full Text] [Related]

  • 16. [Hormone substitution in the menopause: effect on lipids and cardiovascular risk].
    Keller U.
    Schweiz Rundsch Med Prax; 1991 Apr 16; 80(16):413-7. PubMed ID: 2038637
    [Abstract] [Full Text] [Related]

  • 17. Metabolic and vascular effect of progestins in post-menopausal women. Implications for cardioprotection.
    Rosano GM, Vitale C, Silvestri A, Fini M.
    Maturitas; 2003 Dec 10; 46 Suppl 1():S17-29. PubMed ID: 14670642
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular pharmacology of hormone replacement therapy.
    Rosano GM, Panina G.
    Drugs Aging; 1999 Sep 10; 15(3):219-34. PubMed ID: 10503814
    [Abstract] [Full Text] [Related]

  • 19. Women, lipoproteins and cardiovascular disease risk.
    LaRosa JC.
    Can J Cardiol; 1990 May 10; 6 Suppl B():23B-29B. PubMed ID: 2188715
    [Abstract] [Full Text] [Related]

  • 20. [Women and ischemic cardiopathy].
    Assmann G, Davignon J, Fernández Cruz A, Gotto AM, Jacotot B, Lewis B, Paoletti R.
    Rev Clin Esp; 1989 Oct 10; 185(6):308-15. PubMed ID: 2695994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.